Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partners with Atascosa Explor

18 Jun 2008 07:00

RNS Number : 9543W
ViaLogy PLC
18 June 2008
 



ViaLogy partners with Texas exploration group Atascosa to analyse onshore oil fields

Pasadena, 18 June:  ViaLogy PLC (LSE:VIY)a leading innovator of real-time network-centric signal processing platforms, announces that it has entered into an agreement with a Texas-based oil and gas exploration and production company, Atascosa Exploration LLC,  of San Antonio, to use ViaLogy's  unique technology, QuantumRD™, to analyse seismic data for more accurate definition of the extent and density of underground oil reservoirs prior to the commencement of drilling. The data analysis on three prospective Texas-based well sites will begin immediately. Complete results will be delivered by ViaLogy to Atascosa within three weeks, and exploratory drillinto prove the technology will commence soon afterwards.

The problems of predicting oil traps from coarse seismic data analysis have plagued the oil and gas industry for decades. Pinpoint accuracy is essentialPredictions that are just a few feet out can waste millions of dollars.

QuantumRD applies ViaLogy's patented and proven Quantum Resonance Interferometry (QRI™) technology to analyse coarse 2D and 3D seismic signals and extract more detailed and accurate information than has hitherto been possibleFor the first three pilot wells ViaLogy and Atascosa have reached a non-operating interest participation arrangement, which is based on production in excess of their oil trap estimates prior to the QuantumRD analysis. Assuming that the analysis proves successful the two companies have agreed to form a joint venture company or other business arrangement for the commercialisation of Quantum RD within the United States.

Atascosa CEO, John D. Mullins, said, "We are delighted that Atascosa can take the lead in bringing ViaLogy's technology to market. A successful pilot should result in the widespread use of QuantumRD throughout the industry."

 ViaLogy CEO, Robert W. Dean, said, "QuantumRD should increase the accuracy of existing and future seismic petroleum data reduce false positives about where to drill, and have a significant impact on the oil exploration industry. It should also offer ViaLogy opportunity to expand its sales in an adjacent market. Atascosa is the ideal partner for us."

Mr. Dean pointed out that, if the pilot analysis proves successful, the potential for QuantumRD™ iextensive According to Energy Information Administration (EIA)'s 2006 Annual Report, US had over 21 billion barrels of proven oil reserves. Most of the newer discoveries are in smaller fields. However, the number of newer oilfield discoveries has declined from 1400 in 2001 to 30 by 2006Just over 40 new reservoirs were discovered in known US fields in 2006 based on EIA released numbers.

"Due to the high cost of oil today, producers can now afford to bring on line reserves that were previously passed over because of production rate or quantity or quality of reservoir. QuantumRD shines in this environment because it allows a clear definition of reservoir size and shape. Based on EIA released data, wells in the US are now averaging over 5700 feet in depth. As the cost to drill wells between 5,000 and 12,000 feet is now approximately $1.5 million to $4 million dollars, making an accurate prediction of reservoir characteristics is even more of an economic necessity. ViaLogy's preferred business model is ainterpretation fee and overriding royalty interest (ORRI).  Our ability to accurately predict reservoir size and quality should become a required part of the search for hydrocarbons here and abroad."

  For Further Information please contact

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656).

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications

Samantha Robbins / Anna Dunkin +44 (0) 20-7822-0200

 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFDLLFVQBXBBD
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.